Navigation Links
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Date:10/30/2010

BOSTON, Oct. 30 /PRNewswire/ -- Tibotec Pharmaceuticals (Tibotec) announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.  

The results showed that in the four TMC435 treatment groups between 79 and 86 percent of patients were able to stop all therapy at Week-24, according to the response criteria defined in the study protocol. There were no relevant differences for adverse events between TMC435 treatment groups and placebo. TMC435, a hepatitis C protease inhibitor, dosed once daily (q.d.) is being developed jointly by Tibotec Pharmaceuticals and Medivir.

The PILLAR study [Protease Inhibitor TMC435 trial assessing the optimaL dose and duration as once daiLy Anti-viral Regimen] (TMC435-C205; NCT00882908) is an ongoing, five-arm, global phase 2b randomized, double-blind, placebo controlled study in 386 treatment-naive patients. TMC435 was administered in doses of 75mg or 150mg q.d. for either 12 weeks or 24 weeks in combination with 24 weeks of peg-interferon and ribavirin (PR). Patients in the placebo arm receive 24 weeks of placebo plus peg-interferon and ribavirin followed by 24 additional weeks of peg-interferon and ribavirin treatment. The primary endpoint of the study is sustained virologic response at Week-72 (SVR24). The PILLAR study is being conducted in 13 countries in Europe, North America, and Australasia.

Patients receiving TMC435 were allowed to stop all treatment at week 24 when a) HCV RNA levels < 25 IU/mL at week 4  and b) HCV RNA < 25 IU/mL levels at weeks 12, 16 and 20. Patients who did not meet the above resp
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Minerva Neurosciences (NASDAQ: ... of new therapies to treat neuropsychiatric diseases and disorders, ... been appointed vice president of finance and chief accounting ... is a senior executive with more than 20 years ... and life science companies. His background includes the management ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... registry platform, announced that three PatientCrossroads-based patient ... the Phelan-McDermid Syndrome International Registry; and the ... been awarded contracts by the Patient-Centered Outcomes ... creation of a new health data network ...
(Date:7/13/2014)... (Brown University) -- The discovery 30 years ago of ... explosion of nanotechnology research. Now, there appears to be ... Brown University, Shanxi University and Tsinghua University in China ... forms a hollow molecular cage similar to a carbon ... cage structurepreviously only a matter of speculationdoes indeed exist. ...
(Date:7/13/2014)... 2014 Deep Research Report on Global ... in-depth study on the current state of the Nano ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
Breaking Biology Technology:Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3
... April 28 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ... novel zinc finger DNA-binding proteins (ZFPs) for therapeutic ... Thomas G.,Wiggans to the company,s Board of Directors., ... Executive Officer of,Connetics Corporation, a biotechnology company, from ...
... ... product, ... Lucas has joined the Company as vice president,of sales and marketing. ... strategy, building the sales force, and leading the,commercial introduction of the ...
... CHINA, April 28 Simcere,Pharmaceutical Group (NYSE: ... generic pharmaceuticals and manufacturer of the patented,anti-cancer biotech ... has been,informed that one of its existing shareholders, ... beneficially owned by 15,individuals, including certain senior management ...
Cached Biology Technology:Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4AssureRx Adds VP of Sales and Marketing 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3
(Date:7/14/2014)... that could overcome a major cost barrier to ... could replace expensive and environmentally harmful fossil fuels. ... that performs almost as well as cost-prohibitive platinum ... to split water molecules into hydrogen and oxygen. ... than less-expensive catalysts investigated to-date. , "Hydrogen has ...
(Date:7/14/2014)... to reliably and safely make in the laboratory all of ... key step closer to reality. , Writing today in the ... of Wisconsin-Madison stem cell researcher Igor Slukvin reports the discovery ... and turning them into both red and the array of ... is important because it identifies how nature itself makes blood ...
(Date:7/13/2014)... in women suggests that experiencing one or more stressful ... can slow the body,s metabolism, potentially contributing to weight ... day,s stressors before giving them a meal consisting of ... then measured their metabolic rate how long it ... and took measures of blood sugar, triglycerides, insulin and ...
Breaking Biology News(10 mins):Rutgers chemists develop technology to produce clean-burning hydrogen fuel 2Wisconsin scientists find genetic recipe to turn stem cells to blood 2Wisconsin scientists find genetic recipe to turn stem cells to blood 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... Peering deep within the cells of fruit flies, developmental ... University in Philadelphia may have discovered a new way ... If they're right, and the same processes are at ... eventually have implications for improving the understanding of a ...
... change will have major effects on coral reefs ?and has ... from the ARC Centre of Excellence for Coral Reef Studies ... engineering model to predict how much damage a reef is ... sea. , In a paper in the international ...
... unique Mayo Clinic collaboration has revived the healing wisdom ... extract described in a 17th century Dutch herbal text ... from the Atun tree effectively control bacteria that can ... circa 1650. He documented his traditional healing methods in ...
Cached Biology News:Jefferson researchers uncover new way nature turns genes on and off 2Stormy days ahead for coral reefs 2Stormy days ahead for coral reefs 3Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug 2
Request Info...
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... Polymerase I from E. coli ... The enzyme also contains both ... 5'?3' exonuclease activity enables the ... gaps in the DNA as ...
... Stem Cell Expansion Kit - Monolayer Plus is ... NSC expansion as a monolayer in a serum-free ... Plus Media Supplement, which has been optimized for ... al . (1996) Genes & Development 10 ...
Biology Products: